Erratum to: Recombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation

Akira Shirahata · Jun Mimuro · Hoyu Takahashi · Isao Kitajima · Hajime Tsuji ·
Yutaka Eguchi · Tadashi Matsushita · Masahiro Kajiki · Goichi Honda · Yoichi Sakata

Published online: 29 July 2014
© Springer-Verlag Berlin Heidelberg 2014

Erratum to: Eur J Pediatr (2014) 173:303–311
DOI 10.1007/s00431-013-2155-8

The original version of this article unfortunately contains an error in Table 1. The authors had mistakenly indicated an incorrect value in the percent columns under “Neonatal asphyxia/ HIE” and “Others”. The previously erroneous values, however, do not change the conclusion of the publication. The correct version of Table 1 is presented below:

The online version of the original article can be found at: <http://dx.doi.org/10.1007/s00431-013-2155-8>.

A. Shirahata
University of Occupational and Environmental Health, Japan,
Kitakyushu, Fukuoka, Japan

J. Mimuro · H. Takahashi · I. Kitajima · H. Tsuji · Y. Eguchi ·
T. Matsushita · Y. Sakata
The Japanese Society on Thrombosis and Hemostasis Post
Marketing Surveillance Committee for Thrombomodulin Alfa,
Tokyo, Japan

J. Mimuro · Y. Sakata
Division of Cell and Molecular Medicine, Center for Molecular
Medicine, Jichi Medical University, School of Medicine, Tochigi,
Japan

H. Takahashi
Department of Internal Medicine, Niigata Prefectural Kamo Hospital,
Niigata, Japan

I. Kitajima
Department of Clinical Laboratory and Molecular Pathology,
Graduate School of Medical and Pharmaceutical Science, University
of Toyama, Toyama, Japan

H. Tsuji
Department of Blood Transfusion, Kyoto Prefectural University of
Medicine, Kyoto, Japan

Y. Eguchi
Critical and Intensive Care Medicine, Shiga University of Medical
Science, Shiga, Japan

T. Matsushita
Department of Transfusion Medicine, Nagoya University Hospital,
Aichi, Japan

M. Kajiki · G. Honda
Pharmaceuticals Sales Division, Asahi Kasei Pharma Corporation,
Tokyo, Japan

A. Shirahata (✉)
Kita-kyushu Yahata Higashi Hospital, 2-1-17 Nishi-honmachi,
Yahata-higashi-ku, Kita-kyushu, Fukuoka 805-0061, Japan
e-mail: a-shirahata@kitakyu-hp.or.jp

Table 1 Underlying diseases causing DIC and patient characteristics

Patient characteristics		Underlying disease associated with DIC								Total	
		Infections ^b		Neonatal asphyxia/ HIE ^c		Hematological malignancies ^d		Others ^e		<i>n</i>	Percent
		<i>n</i>	Percent	<i>n</i>	Percent	<i>n</i>	Percent	<i>n</i>	Percent		
Gestational age (weeks)	22-27	14	56.0	0	0.0	0	0.0	1	6.7	15	25.0
	28-36	4	16.0	3	18.8	1	25.0	3	20.0	11	18.3
	37-	6	24.0	13	81.3	2	50.0	9	60.0	30	50.0
	Unknown	1	4.0	0	0.0	1	25.0	2	13.3	4	6.7
Birth weight(g)	<999	14	56.0	1	6.3	0	0.0	1	6.7	16	26.7
	1,000-1,499	2	8.0	1	6.3	0	0.0	1	6.7	4	6.7
	1,500-2,499	4	16.0	4	25.0	1	25.0	3	20.0	12	20.0
	2,500-	5	20.0	10	62.5	3	75.0	10	66.7	28	46.7
Type of delivery	Vaginal	9	36.0	8	50.0	1	25.0	8	53.3	26	43.3
	Caesarean	15	60.0	7	43.8	3	75.0	7	46.7	32	53.3
	Unknown	1	4.0	1	6.3	0	0.0	0	0.0	2	3.3
Maternal complications at delivery ^a	Yes	8	34.8	2	12.5	2	50.0	1	6.7	13	22.4
	No	15	65.2	14	87.5	2	50.0	14	93.3	45	77.6

Numbers in bold are the corrected percent values

^a Maternal complications at delivery: threatened labor; placenta previa, premature rupture of membranes, cephalopelvic disproportion, twin pregnancy, placental transfusion syndrome, gestational hypertension, uterine hypotonus, abnormal labor; glaucoma, ulcerative colitis, myotonic dystrophy, mumps

^b Infections: sepsis (*n*=12), intrauterine infection (*n*=3), peritonitis (*n*=3), infection (location unknown) (*n*=2), herpesvirus infectious disease, fungal infection, neonatal infection, urinary tract infection, necrotizing colitis

^c Neonatal asphyxia/HIE: neonatal asphyxia (*n*=13), hypoxic-ischemic encephalopathy (HIE) (*n*=3)

^d Hematological malignancies: acute lymphocytic leukemia (*n*=2), myeloproliferative disorder (*n*=2), transient abnormal myelopoiesis (*n*=2; one with Down syndrome)

^e Others: small for gestational age (*n*=2); shock; metabolic disorder; cytogenetic aberration, gastro-intestinal perforation, imperforate anus repair; hemangioma-thrombocytopenia syndrome, carbamoy phosphate synthetase deficiency, anemia neonatorum, cardiovascular collapse, fetal hydrops, cardiac failure, thrombocytopenia, hemophagocytic syndrome